BOSTON – In summer of 2020, despite the challenges posed by the pandemic, the Sean M. Healey & AMG Center at Massachusetts General Hospital (MGH) and the Northeast ALS (NEALS) Consortium launched the first platform trial for amyotrophic lateral sclerosis (ALS), in which multiple treatments are tested and evaluated simultaneously to accelerate the development of therapies for people with ALS. The trial opened at several sites of the NEALS Consortium and has been enrolling participants to test four investigational products so far.
Drug candidates that enter the platform trial are chosen by a group of expert ALS scientists and members of the Healey Center Science Advisory Committee. Investigators have now selected the next – RNS60 – for possible entry into the trial.
RNS60 is a novel neuroprotective and immune-modulatory agent that has shown significant effects in pre-clinical models of ALS and other neurodegenerative diseases. RNS60 activates intracellular signaling pathways that support mitochondria and have anti-inflammatory effects and thereby promote cellular survival and differentiation. The drug is being developed by Revalesio Corporation, a clinical stage pharmaceutical company dedicated to developing treatments for neurological disorders.
To read the full article, click here: https://www.massgeneral.org/news/press-release/Revalesio-signs-agreement-to-design-trial-with-rns60-for-the-healeyals-platform-trial